Synergy Pharmaceuticals’ (SGYP) “Buy” Rating Reiterated at BTIG Research
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a research report issued on Friday.
Several other equities analysts also recently commented on the company. Rodman & Renshaw reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Synergy Pharmaceuticals in a research report on Monday, May 23rd. Canaccord Genuity reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Synergy Pharmaceuticals in a research report on Monday, May 23rd. HC Wainwright set a $15.00 price objective on Synergy Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, September 8th. Roth Capital reaffirmed a “buy” rating and issued a $6.50 price objective on shares of Synergy Pharmaceuticals in a research report on Thursday, May 26th. Finally, Zacks Investment Research downgraded Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 24th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $9.75.
Synergy Pharmaceuticals (NASDAQ:SGYP) traded down 4.202% during trading on Friday, hitting $5.585. The stock had a trading volume of 6,127,910 shares. Synergy Pharmaceuticals has a 52-week low of $2.50 and a 52-week high of $7.72. The stock’s 50-day moving average is $4.80 and its 200-day moving average is $3.77. The stock’s market capitalization is $1.00 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/16/synergy-pharmaceuticals-sgyp-buy-rating-reiterated-at-btig-research.html
Synergy Pharmaceuticals (NASDAQ:SGYP) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by $0.03. On average, analysts predict that Synergy Pharmaceuticals will post ($1.05) earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of SGYP. State Treasurer State of Michigan purchased a new position in Synergy Pharmaceuticals during the second quarter worth about $152,000. Societe Generale bought a new stake in shares of Synergy Pharmaceuticals during the second quarter worth $4,729,000. California State Teachers Retirement System increased its stake in shares of Synergy Pharmaceuticals by 79.5% in the second quarter. California State Teachers Retirement System now owns 380,444 shares of the biopharmaceutical company’s stock worth $1,446,000 after buying an additional 168,486 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Synergy Pharmaceuticals by 38.0% in the second quarter. Bank of New York Mellon Corp now owns 872,174 shares of the biopharmaceutical company’s stock worth $3,314,000 after buying an additional 240,196 shares during the last quarter. Finally, Cheyne Capital Management UK LLP bought a new stake in shares of Synergy Pharmaceuticals during the second quarter worth $250,000. 56.67% of the stock is currently owned by institutional investors and hedge funds.
Synergy Pharmaceuticals Company Profile
Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.
Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Synergy Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.